Skip to content
Screener

Septerna, Inc. SEPN Net Change in Cash

Net Change in Cash at other companies

Amgen logo
AmgenAMGN
$1.95B+349%
Tectonic Therapeutics logo
Tectonic TherapeuticsTECX
-$17.49M-111%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$74.44M-49.3%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$25.41M+3,080%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$3.51M-142%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$320.25M+1,018%

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.78B+240%
Enterprise value$1.73B+383%
P/S24.7×-696×

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Septerna, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:08 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216759
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Maturities of marketable securities82,24545,223
Net cash used in investing activities(23,817)(4,874)
Cash flows from financing activities:
Proceeds from exercise of stock options33366
Net cash provided by financing activities33366
Net decrease in cash, cash equivalents and restricted cash(49,117)(28,151)
Cash, cash equivalents and restricted cash, beginning of period121,627239,101
Cash, cash equivalents and restricted cash, end of period$72,510$210,950

Item 1. Condensed Financial Statements.

FAQ

What is Septerna, Inc.'s net change in cash?
Septerna, Inc. (SEPN) reported net change in cash of -$49.12M in Q1 2026.
How has Septerna, Inc.'s net change in cash changed year-over-year?
Septerna, Inc.'s net change in cash decreased by 74.5% year-over-year, from -$28.15M to -$49.12M.
What is the long-term trend for Septerna, Inc.'s net change in cash?
Over 2 years (2023 to 2025), Septerna, Inc.'s net change in cash has grown at a 42.4% compound annual growth rate (CAGR), from $57.92M to -$117.47M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Septerna, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude